Table 2.
Subgroup analysis of the association between Rab27 expression and survival.
| Subgroup | Number of studies | Number of patients | Pooled HR (95% CI) | p value | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 (%) | p value | |||||
| Cancer type | ||||||
| Colorectal cancer | 2 | 225 | 0.90 (0.15–5.44) | 0.911 | 90.3 | 0.001 |
| Lung cancer | 2 | 213 | 2.17 (1.36–3.47) | 0.001 | 0.0 | 0.369 |
| Pancreatic cancer | 2 | 372 | 2.77 (1.50–5.11) | 0.001 | 0.0 | 0.850 |
| Others | 4 | 624 | 6.67 (4.11–10.80) | < 0.001 | 0.0 | 0.398 |
| Sample size | ||||||
| Fewer than 100 | 2 | 213 | 2.17 (1.36–3.47) | 0.001 | 0.0 | 0.369 |
| More than 100 | 8 | 1221 | 3.07 (1.42–6.65) | 0.004 | 82.8 | < 0.001 |
| Survival outcome | ||||||
| DSS | 3 | 506 | 3.57 (1.28–9.99) | 0.015 | 68.7 | 0.022 |
| OS | 7 | 928 | 2.33 (1.18–4.60) | 0.015 | 80.0 | < 0.001 |
| Protein type | ||||||
| Rab27A | 3 | 450 | 1.73 (0.30–9.89) | 0.538 | 87.7 | < 0.001 |
| Rab27B | 7 | 984 | 3.27 (2.04–5.24) | < 0.001 | 58.3 | 0.019 |
CI confidence interval, DSS disease-specific survival, HR hazard ratio, OS overall survival.